-
N287850-25mgNexinhib20 is a specific Rab27a-JFC1 interaction inhibitor with a calculated IC50 of 2.6 μM. Nexinhib20 significantly inhibits superoxide anion production. Nexinhib20 efficiently decreases exocytosis of azurophilic granules in neutrophils stimulated
-
N287850-5mgNexinhib20 is a specific Rab27a-JFC1 interaction inhibitor with a calculated IC50 of 2.6 μM. Nexinhib20 significantly inhibits superoxide anion production. Nexinhib20 efficiently decreases exocytosis of azurophilic granules in neutrophils stimulated
-
N287392-100mgPotent and selective irreversible MAGL inhibitor: membrane permeable and brain penetrant.
-
N287392-10mgPotent and selective irreversible MAGL inhibitor: membrane permeable and brain penetrant.
-
N287392-25mgPotent and selective irreversible MAGL inhibitor: membrane permeable and brain penetrant.
-
N287392-50mgPotent and selective irreversible MAGL inhibitor: membrane permeable and brain penetrant.
-
N287392-5mgPotent and selective irreversible MAGL inhibitor: membrane permeable and brain penetrant.
-
Ab177922-100μgNGM120 (anti-GFRAL) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL
-
Ab177922-10mgNGM120 (anti-GFRAL) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL
-
Ab177922-1mgNGM120 (anti-GFRAL) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL
-
Ab177922-5mgNGM120 (anti-GFRAL) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL
-
N286797-10mgNHI-2 is a potent inhibitor of LDH-A. NHI-2 is an efficient anti-glycolytic agent. NHI-2 has the potential for the research of cancer disease.